Healthcare Services

One of the Major Drivers of the Metastatic Prostate Cancer Market Is the Rising Demand For Personalized Treatments Enhancing Market Growth Due To Advances In Genomic Profiling And Biomarker Testing

April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Metastatic Prostate Cancer Market By 2030 Starting From Its 2026 Size?

The market size for metastatic prostate cancer has demonstrated robust expansion over recent years. It is projected to expand from $8.81 billion in 2025 to $9.57 billion by 2026, representing a compound annual growth rate (CAGR) of 8.6%. This historical growth can be attributed to several factors, including the rising incidence of advanced prostate cancer cases, the expansion of oncology treatment centers, improved survival rates through early intervention, the availability of multiple therapeutic options, and increased use of chemotherapy protocols.

The metastatic prostate cancer market size is projected to experience substantial growth in the upcoming years. It is forecast to expand to $13.16 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.3%. This anticipated growth throughout the forecast period stems from the increasing development of novel immunotherapies, the rising adoption of personalized cancer treatments, the expansion of clinical trials for advanced therapies, the growing utilization of radiopharmaceutical treatments, and an increasing focus on improving quality-of-life outcomes for patients. Significant trends during this period are expected to include the escalating adoption of targeted and hormonal therapies, the rising application of combination treatment regimens, a heightened focus on precision oncology approaches, the broadening of advanced diagnostic and biomarker testing, and an enhanced emphasis on patient-centered treatment strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25833&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Metastatic Prostate Cancer Market?

The increasing requirement for personalized treatments is projected to propel the expansion of the metastatic prostate cancer market in the coming years. Personalized treatments involve medical strategies tailored to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The growing demand for personalized treatments is attributed to the increasing availability of genomic profiling and biomarker testing; these technologies assist in identifying specific mutations and biological markers, thereby enabling clinicians to select therapies that are more likely to be effective for each individual. Personalized treatment approaches, such as biomarker-guided therapies and gene-targeted drugs, are transforming the management of metastatic prostate cancer by aligning specific therapies with each patient’s unique tumor profile to enhance effectiveness and minimize side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, a significant rise compared to 6 in the year 2022. Therefore, the escalating demand for personalized treatments is a key driver for the growth of the metastatic prostate cancer market.

Which Segment Categories Define The Metastatic Prostate Cancer Market?

The metastatic prostate cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Immunotherapy, Hormonal Therapy, Radiation Therapy, Other Treatments

2) By Route of Administration: Oral, Parenteral Route, Intravenous

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By End User: Hospitals, Clinics, Cancer Centers, Research Laboratories, Other End-Users

Subsegments:

1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

2) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine Therapies

3) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors, Combined Androgen Blockade (CAB)

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiotherapy (SBRT), Radiopharmaceutical Therapy, Intensity-Modulated Radiation Therapy (IMRT)

5) By Other Treatments: Targeted Therapy, Bone-Targeted Therapy, Clinical Trial Drugs, Palliative Therapy

What Trends Are Projected To Affect The Metastatic Prostate Cancer Market?

Leading companies in the metastatic prostate cancer market are concentrating on technological innovations in cancer treatment, such as advanced targeted radioligand technology, to deliver precise radiation to cancer cells while safeguarding healthy tissue. This advanced targeted radioligand technology is a therapy that combines a molecule targeting prostate specific membrane antigen PSMA with a radioactive isotope, enabling the targeted destruction of cancer cells throughout the body. For example, in March 2025, Novartis AG, a Switzerland-based multinational pharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval for Pluvicto for earlier administration in patients with PSMA-positive metastatic castration-resistant prostate cancer. Pluvicto itself is composed of a prostate-specific membrane antigen (PSMA) targeting ligand linked to a beta-emitting radionuclide; it operates by binding to PSMA-expressing tumor cells and delivering localized radiation to eliminate them. Its distinctive attributes include strong tumor specificity, a favorable safety profile, and the potential for combination with other therapies. Its applications cover advanced-stage prostate cancer treatment, particularly for patients who have progressed after androgen deprivation therapy. The observed benefits include improved progression-free survival, targeted cytotoxicity, reduced off-target effects, and enhanced patient outcomes.

Who Are The Top Companies Competing In The Metastatic Prostate Cancer Market?

Major companies operating in the metastatic prostate cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen Group, Exelixis Inc., Ferring Pharmaceuticals, Dendreon Pharmaceuticals LLC, Hinova Pharmaceuticals Inc., Janux Therapeutics Inc., Clarity Pharmaceuticals Ltd., Convergent Therapeutics Inc., Johnson & Johnson, Sanofi, Eli Lilly And Company, Roche Holding AG, Takeda Pharmaceutical Company Limited

Read the full metastatic prostate cancer market report here:

https://www.thebusinessresearchcompany.com/report/metastatic-prostate-cancer-global-market-report

Which Regions Are Projected To Dominate The Metastatic Prostate Cancer Market In The Coming Years?

North America was the largest region in the metastatic prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Metastatic Prostate Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25833&type=smp

Browse Through More Reports Similar to the Global Metastatic Prostate Cancer Market 2026, By The Business Research Company

Melanoma Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/melanoma-therapeutics-global-market-report

Malignant Melanoma Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

Melanoma Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/melanoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795